Banner - NPPA Connect

Opinion|Videos|April 8, 2025

Prior and Current Treatments for Patients With GPP

Author(s)Aaron S. Farberg, MD, Tina Bhutani, MD, MAS, Christopher G. Bunick, MD, PhD

Panelists discuss how prior and current treatments for patients with generalized pustular psoriasis (GPP) have evolved from traditional systemic therapies with significant limitations to newer targeted biologics and small molecules that specifically address the underlying IL-36 pathway dysregulation, offering improved efficacy and safety profiles for this rare but severe condition.

Episodes in this series

4 experts are featured in this series.

EP. 1 The Prevalence and Characteristics of GPP

4 experts are featured in this series.

EP. 2 Clinical Experience and Diagnosis of GPP

4 experts are featured in this series.

EP. 3 The Challenges of Diagnosis and Management of GPP

4 experts are featured in this series.

EP. 4 Quality of Life Impact: Supporting Patients With GPP

4 experts are featured in this series.

EP. 5 Recognizing the Flares and Triggers of GPP

4 experts are featured in this series.

EP. 6 Prior and Current Treatments for Patients With GPP

4 experts are featured in this series.

EP. 7 Case 1: Experts on a GPP Emergency Case and Effisayil 1 Trial Results

4 experts are featured in this series.

EP. 8 Case 2: Poorly Managed GPP Flares and Effisayil 2 Trial Results

4 experts are featured in this series.

EP. 9 Case 3: High-Risk Patient with GPP Treatment Approach

4 experts are featured in this series.

EP. 10 What Lies Ahead for GPP Diagnosis and Management

EP. 11 Diagnosing and Managing GPP: Top Insights From the Experts

EP. 11 Diagnosing and Managing GPP: Top Insights From the Experts

EP. 12 FAQtual Insights: Systemic Risk and Targeted Therapy in GPP

EP. 12 FAQtual Insights: Systemic Risk and Targeted Therapy in GPP

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Adaptive Learning

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Trending on Dermatology Times

Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension

Expanding Oral JAK Inhibitor Options for Children With AD and Alopecia Areata

Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine

Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease

Oral Minoxidil's Steady-State Release Avoids Cardiotoxic Peaks